.Merck trumps revenues requirements, increases purchases outlook on solid demand for best medicines like Keytruda CNBCMerck & Co. (MRK US) Beats Revenue Estimates as Keytruda Sales Surge BloombergMerck Stock: Pharma Giant Posts Sturdy End Results, However Outlook Falls Short Financier's Company DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck trumps profit and purchases expectations in the middle of Keytruda strength, yet offers blended full-year outlook MarketWatch.